# Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction

> **NCT01083537** · PHASE1,PHASE2 · TERMINATED · sponsor: **University Health Network, Toronto** · enrollment: 1 (actual)

## Conditions studied

- Ovarian Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer
- Bowel Obstruction

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01083537
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01083537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01083537, "Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01083537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*